Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03246802 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Partial Prostate Salvage High Dose Rate Brachytherapy

Study acronym: SalvageHDR
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Eligibility criteria shortened, about 120 words Secondary endpoints revised (7) · Study description expanded, about 9 words · Site contact updatedv8 Show 3 more changesShow less
    • Secondary endpoints revised (7)
    • Study description expanded, about 9 words
    • Site contact updated

    See this version in full on ClinicalTrials.gov ↗

  2. Eligibility criteria expanded, about 12 words Secondary endpoints revised (7) · Site contact updatedv7 Show 2 more changesShow less
    • Secondary endpoints revised (7)
    • Site contact updated

    See this version in full on ClinicalTrials.gov ↗

  3. Primary completion date: Dec 31, 2024 to Jan 1, 2032 Completion date: Dec 31, 2027 to Jan 1, 2037 · Eligibility criteria expanded, about 13 words · Secondary endpoints: 6 to 7 · 1 morev6 Show 4 more changesShow less
    • Completion date: Dec 31, 2027 to Jan 1, 2037
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: 6 to 7
    • Site contact updated

    See this version in full on ClinicalTrials.gov ↗

  4. Enrollment target: 15 to 30 Primary completion date: Dec 31, 2022 to Dec 31, 2024 · Site contact updatedv5 Show 2 more changesShow less
    • Primary completion date: Dec 31, 2022 to Dec 31, 2024
    • Site contact updated
  5. 2 versions Re-verified since Jan 23, 2020, no change to tracked fieldsv3-v4
  6. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Oct 1, 2017 to Jan 1, 2018 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Oct 1, 2017 to Jan 1, 2018
    • Site details revised
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A dose-response relationship for radiation in the management of prostate cancer is well established. Local recurrence of prostate cancer after external beam radiotherapy occurs in at least 40% of patients treated because of inability to deliver sufficient dose through external beam techniques. These patients respond well to re-irradiation using brachytherapy with about 50% of selected patients remaining free of recurrence 5 years after salvage. Advanced imaging using multiparametric Magnetic Resonance Imaging (mpMRI) allows identification of the site of recurrence, permitting partial prostate salvage brachytherapy. There is extensive literature on Low Dose Rate salvage brachytherapy but less on High Dose Rate.
Trial Details
NCT Number NCT03246802
Lead Sponsor British Columbia Cancer Agency
Conditions Recurrent Prostate Cancer
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov